CytoGen, Inc.
KKRX:2173302,505.00
KRW
-140.00
(-5.29%)
ISIN
KR7217330000
Return %
Stock
S&P 500
1Y
-23.28
13.14
3Y
-81.01
80.78
5Y
-88.46
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 39
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Nov 22, 2018
- Website
- cytogenlab.com
- Similar Companies
- Business
- CytoGen, Inc. is a South Korea-based biotechnology company specializing in liquid biopsy technologies, precision oncology diagnostics, and circulating tumor cell (CTC) isolation and analysis platforms. Founded in 2010 and headquartered in Seoul, South Korea, the company develops and commercializes non-invasive clinical diagnostic systems that capture and analyze viable, intact circulating tumor cells from peripheral whole blood to facilitate cancer diagnosis, prognosis, therapeutic monitoring, and companion diagnostics. CytoGen operates across integrated biomedical instrumentation, consumable bio-chips, and clinical testing segments, offering a portfolio of products and services that includes automated CTC isolation and harvesting instruments under the Smart Biopsy platform; high-density microfluidic bio-chips utilizing precision pore-filtration technology to separate living tumor cells without damaging cellular morphology; specialized biomarker staining and assay reagent kits; single-cell multi-omics analysis services comprising next-generation sequencing (NGS), digital polymerase chain reaction (dPCR), and RNA expression profiling; and customized companion diagnostic (CDx) development and contract research organization (CRO) services for oncology drug screening and translational research. The company serves hospitals, academic research institutes, clinical laboratories, and biopharmaceutical developers across South Korea, the United States, Japan, and Europe. In recent corporate and operational developments, CytoGen has expanded its global clinical footprint by acquiring CLIA-certified laboratory infrastructure in the United States to accelerate commercial liquid biopsy testing services, establishing strategic partnerships with international pharmaceutical companies and research institutions for companion diagnostic co-development, and expanding its multi-omics liquid biopsy pipeline to integrate circulating tumor DNA (ctDNA) and extracellular vesicle analysis alongside its core live CTC platform.